A decreased risk of hospitalization for CVDs was found among patients with a history of visit for CVDs (aHR, 0.73; 95% CI, 0.56–0.97) or with >2.5 years’ duration of type 2 diabetes (aHR, 0.77; 95% CI, 0.66–0.91) in the DPP-4 inhibitors versus glimepiride group. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.